DDInter255 DDInter837
Busulfan is a bifunctional alkylating agent, having a selective immunosuppressive effect on bone marrow. It is not a structural analog of the nitrogen mustards. It has been used in the palliative treatment of chronic myeloid leukemia (myeloid leukemia, chronic), but although symptomatic relief is provided, no permanent remission is brought about. According to the Fourth Annual Report on Carcinogens (NTP 85-002, 1985), busulfan is listed as a known carcinogen.
Golimumab is a human IgG1қ monoclonal antibody derived from immunizing genetically engineered mice with human TNFα. Golimumab binds and inhibits soluble and transmembrane human TNFα. Increased TNFα is associated with chronic inflammation. Thus golimumab is indicated for use in adults (i) as an adjunct to methotrexate treatment in patients with moderate to severe active rheumatoid arthritis (RA), (ii) alone or as an adjunct to methotrexate treatment in patients with active psoriatic arthritis (PsA), (iii) as a single agent in patients with active ankylosing spondylitis (AS), and (iv) as a single agent in patients with moderate to severe ulcerative colitis (UC) who require chronic steroids or have experienced intolerance or only a partial response to previous medications. In the U.S. and Canada, golimumab is marketed under the brand name Simponi®. The FDA label includes a black box warning of serious infections and malignancy. Additionally in children and adolescents taking golimumab, there have been lymphoma and other malignancies observed.
Busulfan {u} (Compound) binds {v} (Gene) GSTA2
GSTA2 {u} (Gene) is bound by {v} (Compound) Vitamin E
Vitamin E {u} may cause a minor interaction that can limit clinical effects when taken with {v} Golimumab
Busulfan {u} (Compound) binds {v} (Gene) CYP3A4
CYP3A4 {u} (Gene) is bound by {v} (Compound) Nifedipine
Nifedipine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Golimumab
Busulfan {u} (Compound) binds {v} (Gene) GSTP1
GSTP1 {u} (Gene) is bound by {v} (Compound) Oxaliplatin
Oxaliplatin {u} may lead to a major life threatening interaction when taken with {v} Golimumab
Busulfan {u} (Compound) downregulates {v} (Gene) MTHFD2
MTHFD2 {u} (Gene) is upregulated by {v} (Compound) Nifedipine
Nifedipine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Golimumab
Busulfan {u} (Compound) downregulates {v} (Gene) MTHFD2
MTHFD2 {u} (Gene) is downregulated by {v} (Compound) Colchicine
Colchicine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Golimumab
Busulfan {u} (Compound) downregulates {v} (Gene) DDX42
DDX42 {u} (Gene) is upregulated by {v} (Compound) Azacitidine
Azacitidine {u} may lead to a major life threatening interaction when taken with {v} Golimumab
Busulfan {u} (Compound) upregulates {v} (Gene) SLC35A1
SLC35A1 {u} (Gene) is downregulated by {v} (Compound) Nifedipine
Nifedipine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Golimumab
Busulfan {u} (Compound) downregulates {v} (Gene) DDX42
DDX42 {u} (Gene) is downregulated by {v} (Compound) Daunorubicin
Daunorubicin {u} may lead to a major life threatening interaction when taken with {v} Golimumab
Busulfan {u} (Compound) downregulates {v} (Gene) MTHFD2
MTHFD2 {u} (Gene) is downregulated by {v} (Compound) Pitavastatin
Pitavastatin {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Golimumab
Busulfan {u} (Compound) upregulates {v} (Gene) SLC35A1
SLC35A1 {u} (Gene) is upregulated by {v} (Compound) Pitavastatin
Pitavastatin {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Golimumab
Busulfan (Compound) binds GSTA2 (Gene) and GSTA2 (Gene) is bound by Vitamin E (Compound) and Vitamin E may cause a minor interaction that can limit clinical effects when taken with Golimumab
Busulfan (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Nifedipine (Compound) and Nifedipine may cause a moderate interaction that could exacerbate diseases when taken with Golimumab
Busulfan (Compound) binds GSTP1 (Gene) and GSTP1 (Gene) is bound by Oxaliplatin (Compound) and Oxaliplatin may lead to a major life threatening interaction when taken with Golimumab
Busulfan (Compound) downregulates MTHFD2 (Gene) and MTHFD2 (Gene) is upregulated by Nifedipine (Compound) and Nifedipine may cause a moderate interaction that could exacerbate diseases when taken with Golimumab
Busulfan (Compound) downregulates MTHFD2 (Gene) and MTHFD2 (Gene) is downregulated by Colchicine (Compound) and Colchicine may cause a moderate interaction that could exacerbate diseases when taken with Golimumab
Busulfan (Compound) downregulates DDX42 (Gene) and DDX42 (Gene) is upregulated by Azacitidine (Compound) and Azacitidine may lead to a major life threatening interaction when taken with Golimumab
Busulfan (Compound) upregulates SLC35A1 (Gene) and SLC35A1 (Gene) is downregulated by Nifedipine (Compound) and Nifedipine may cause a moderate interaction that could exacerbate diseases when taken with Golimumab
Busulfan (Compound) downregulates DDX42 (Gene) and DDX42 (Gene) is downregulated by Daunorubicin (Compound) and Daunorubicin may lead to a major life threatening interaction when taken with Golimumab
Busulfan (Compound) downregulates MTHFD2 (Gene) and MTHFD2 (Gene) is downregulated by Pitavastatin (Compound) and Pitavastatin may cause a moderate interaction that could exacerbate diseases when taken with Golimumab
Busulfan (Compound) upregulates SLC35A1 (Gene) and SLC35A1 (Gene) is upregulated by Pitavastatin (Compound) and Pitavastatin may cause a moderate interaction that could exacerbate diseases when taken with Golimumab